Effects of AS2586114, a soluble epoxide hydrolase inhibitor, on hyperlocomotion and prepulse inhibition deficits in mice after administration of phencyclidine

Pharmacology Biochemistry and Behavior

Volumn 110, Issue , 2013, Pages 98-103

  Ma, Min ^a   Ren, Qian ^a   Fujita, Yuko ^a   Ishima, Tamaki ^a   Zhang, Ji Chun ^a   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Antipsychotic drug; Epoxyeicosatrienoic acids; Phencyclidine; Prepulse inhibition; Soluble epoxide hydrolase

Indexed keywords

AS 2586114; CLOZAPINE; HYDROLASE INHIBITOR; PHENCYCLIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; ATTENUATION; BEHAVIOR DISORDER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; HABITUATION; HYPERLOCOMOTION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PREPULSE INHIBITION; PREPULSE INHIBITION DEFICIT; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME;

MUS;

ANTIPSYCHOTIC DRUG; EPOXYEICOSATRIENOIC ACIDS; PHENCYCLIDINE; PREPULSE INHIBITION; SOLUBLE EPOXIDE HYDROLASE;

ANIMALS; BEHAVIOR, ANIMAL; BENZOATES; BICYCLO COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EPOXIDE HYDROLASES; EXCITATORY AMINO ACID ANTAGONISTS; LOCOMOTION; MALE; MICE; PHENCYCLIDINE;

EID: 84879832120     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2013.06.005     Document Type: Article

References (51)

1. Arand M, Cronin A, Adamska M, Oesch F. Epoxide hydrolases: structure, function, mechanism, and assay. Methods Enzymol 2005;400:569-88.
2. Bakshi VP, Swerdlow NR, Geyer MA. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 1994;271:787-94. (Pubitemid 24377766)
3. Braff DL, Geyer MA. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 1990;47:181-8. (Pubitemid 20058094)
4. Chen H, Wu J, Zhang J, Fujita Y, Ishima T, Iyo M, et al. Protective effects of antioxidant sulforaphane on the behavioral changes and neurotoxicity in mice after administration of methamphetamine. Psychopharmacology (Berl) 2012;222:37-45.
5. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 1996;3:241-53. (Pubitemid 26058365)
6. Do KQ, Conus P, Cuenod M. Redox dysregulation and oxidative stress in schizophrenia: nutrigenetics as a challenge in psychiatric disease prevention. World Rev Nutr Diet 2010;101:131-53.
7. Egerton A, Reid L, McGregor S, Cochran SM, Morris BJ, Pratt JA. Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats. Psychopharmacology (Berl) 2008;198:37-49.
8. Fang X. Soluble epoxide hydrolase: a novel target for the treatment of hypertension. Recent Pat Cardiovasc Drug Discov 2006;1:67-72.
9. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 2001;156:117-54. (Pubitemid 32702206)
10. 1A receptors. Eur Neuropsychopharmacol 2008;18:448-54.
11. Hashimoto K. The NMDA receptor hypofunction hypothesis for schizophrenia and glycine modulatory sites on the NMDA receptors as potential therapeutic drugs. Clin Psychopharmacol Neurosci 2006;4:3-10. (Pubitemid 44352184)
12. Hashimoto K. Glycine transportor-1: a potential therapeutic target for schizophrenia. Curr Pharm Des 2011;17:112-20.
13. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, et al. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 2003;60:572-6. (Pubitemid 36682314)
14. Hashimoto K, Okamura N, Shimizu E, Iyo M. Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs. Curr Med Chem Cent Nerv Syst Agents 2004;4:147-54. (Pubitemid 38639374)
15. Hashimoto K, Fujita Y, Shimizu E, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur J Pharmacol 2005a;519:114-7. (Pubitemid 43181173)
16. Hashimoto K, Shimizu E, Iyo M. Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Curr Psychiatry Rev 2005b;1:151-63.
17. Hashimoto K, Fujita Y, Ishima T, Hagiwara H, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: role of α7 nicotinic receptors. Eur J Pharmacol 2006;553:191-5. (Pubitemid 44779614)
18. Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology 2007;32:514-21.
19. Hashimoto K, Fujita Y, Ishima T, Chaki S, Iyo M. Phencyclidine-induced cognitive deficits inmice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine. Eur Neuropsychopharmacol 2008a;18: 414-21. (Pubitemid 351608551)
20. Hashimoto K, Ishima T, Fujita Y, Matsuo M, Kobashi T, Takahagi M, et al. Phencyclidineinduced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective α7 nicotinic receptor agonist SSR180711. Biol Psychiatry 2008b;63:92-7. (Pubitemid 350234890)
21. Hashimoto K, Fujita Y, Horio M, Kunitachi S, Iyo M, Ferraris D, et al. Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol Psychiatry 2009;65:1103-6.
22. Hashimoto K, Fujita Y, Horio M, Hagiwara H, Tanibuchi Y, Iyo M. Effects of cilostazol on dizocilpine-induced hyperlocomotion and prepulse inhibition deficits in mice. Clin Psychopharmacol Neurosci 2010;8:74-8.
23. Hashimoto K, Malchow B, Falkai P, Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 2013. [in press].
24. Imig JD. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev 2012;92:101-30.
25. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 2009;8:794-805.
26. Ishikawa M, Hashimoto K. α7 nicotinic receptor: a potential therapeutic target for schizophrenia. Curr Pharm Des 2011;17:121-9.
27. Javitt DC, Lindsley RW. Effects of phencyclidine on prepulse inhibition of acoustic startle response in the macaque. Psychopharmacology (Berl) 2001;156:165-8. (Pubitemid 32702208)
28. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-8.
29. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999;20:201-25. (Pubitemid 29067401)
30. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51: 199-214. (Pubitemid 24081509)
31. Krystal JH, D'Souza DC, Petrakis IL, Belger A, Berman RM, Charney DS, et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 1999;7:125-43. (Pubitemid 30240826)
32. Marowsky A, Burgener J, Falck JR, Fritschy JM, Arand M. Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism. Neuroscience 2009;163:646-61.
33. Matsuzawa D, Hashimoto K. Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia. Antioxid Redox Signal 2011;15:2057-65.
34. Miura M, Sato I, Kiyohara H, Yokoyama K, Takakura K, Terada H, Yamaguchi T, Amano Y. Cyclic amino compound, or salt thereof. JP2011-16743; 2011.
35. Morisseau C. Role of epoxide hydrolases in lipid metabolism. Biochimie 2013;95: 91-5.
36. Morisseau C, Hammock BD. Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. Annu Rev Pharmacol Toxicol 2013;53:37-58.
37. Niitsu T, Iyo M, Hashimoto K. Sigma-1 receptor agonists as therapeutic drugs for cognitive impairments in neuropsychiatric disease. Curr Pharm Des 2012;18:875-83.
38. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999;285: 1276-9. (Pubitemid 29398616)
39. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52:998-1007.
40. Perry W, Geyer MA, Braff DL. Sensorimotor gating and thought disturbance measured in close temporal proximity in schizophrenic patients. Arch Gen Psychiatry 1999;56: 277-81. (Pubitemid 29125137)
41. Reddy R, Reddy R. Antioxidant therapeutics for schizophrenia. Antioxid Redox Signal 2011;15:2047-55.
42. Shirai Y, Fujita Y, Hashimoto K. Effects of the antioxidant sulforaphane on hyperlocomotion and prepulse inhibition deficits in mice after administration of phencyclidine. Clin Psychopharmacol Neurosci 2012;10:94-8.
43. Swerdlow NR, Braff DL, Taaid N, Geyer MA. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 1994;51:139-54. (Pubitemid 24985903)
44. Tanibuchi Y, Fujita Y, Kohno M, Ishima T, Takatsu Y, Iyo M, et al. Effects of quetiapine on phencyclidine-induced cognitive deficits in mice: a possible role of α1-adrenoceptors. Eur Neuropsychopharmacol 2009;19:861-7.
45. Yang B, Graham L, Dikalov S, Mason RP, Falck JR, Liao JK, et al. Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol 2001;60:310-20. (Pubitemid 32678296)
46. Yao JK, Keshavan MS. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal 2011;15:2011-35.
47. Yee BK, Chang DL, Feldon J. The effects of dizocilpine and phencyclidine on prepulse inhibition of the acoustic startle reflex and on prepulse-elicited reactivity in C57BL6 mice. Neuropsychopharmacology 2004;29:1865-77. (Pubitemid 39336798)
48. Yoshida T, Iyo M, Hashimoto K. Recent advances in the potential therapeutic drugs for cognitive deficits in schizophrenia. Curr Psychiatry Rev 2012;8:140-50.
49. Zhang L, Shirayama Y, Iyo M, Hashimoto K. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 2007a;32:2004-10. (Pubitemid 47258509)
50. Zhang W, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C, et al. Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab 2007b;27: 1931-40. (Pubitemid 350129162)
51. Zhang W, Otsuka T, Sugo N, Ardeshiri A, Alhadid YK, Iliff JJ, et al. Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. Stroke 2008;39: 2073-8.